The abstract is read at the publisher; the summary is JClub's.
Daily oral edaravone (FNP122) 100 mg once daily did not significantly slow ALSFRS-R functional decline versus placebo at 48 weeks in a broad ALS population.
- Why it matters: Oxidative stress is linked to amyotrophic lateral sclerosis, but prior edaravone benefit was limited to a subset and shorter follow-up, leaving uncertainty for wider patients over longer periods.
- What they did: In a multicentre, double-blind phase 3 randomized trial across 37 hospitals in 12 countries, adults with ALS ≤24 months since symptom onset received edaravone 100 mg/day or placebo in a 2:1 ratio, with ALSFRS-R change assessed at week 48.
- The result: At 48 weeks, ALSFRS-R change was -12·6 versus -13·4 points, with a least squares mean difference of 0·78 (95% CI -1·44 to 3·00, p=0·49); treatment-emergent adverse events were similar (88% vs 85%), so results do not support use at this dose for general ALS progression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.